{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:27:47Z","timestamp":1773815267668,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Introduction<\/jats:title>\n Early identification of patients with high cardiorenal risk and timely targeted interventions are critical in managing type 2 diabetes (T2D). Although we previously developed a multivariable risk score to predict diabetic kidney disease (DKD), its ability to stratify cardiorenal risk in T2D patients with established high cardiovascular risk remains unknown.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this\n post-hoc<\/jats:italic>\n analysis of the ELIXA trial, 2,635 T2D participants without baseline DKD were stratified into different risk groups (low-, moderate-, high-, and very high-risk group) using the previously developed risk score (incorporating nine simple clinical indicators: age, body mass index, hemoglobin A1c, systolic blood pressure, high-density lipoprotein cholesterol, triglycerides, smoking, diabetic retinopathy, and urinary albumin-to-creatinine ratio [UACR]). Patients were followed for renal outcomes (DKD incidence and progression) and cardiovascular outcomes (major adverse cardiovascular events [MACEs] and heart failure [HF]).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The risk score demonstrated strong, graded associations with cardiorenal outcomes. Over 108 weeks of renal follow-up, a progressive increase in DKD incidence was observed across risk strata (52.5% vs. 13.5% in the very high- vs. low-risk groups; relative risks [RR] 3.89, 95% confidence interval [CI] 2.82\n \u2013<\/jats:bold>\n 5.38,\n P<\/jats:italic>\n &lt; 0.001). This graded pattern extended to other key events of renal disease progression: macroalbuminuria (5.1% vs. 0.8%; RR 9.37, 95% CI 2.41\n \u2013<\/jats:bold>\n 36.46,\n P<\/jats:italic>\n = 0.001), a \u226540% decline in estimated glomerular filtration rate (eGFR, 3.4% vs. 0.2%; RR 17.72, 95% CI 1.58\n \u2013<\/jats:bold>\n 198.82,\n P<\/jats:italic>\n = 0.020), and rapid renal function decline (44.2% vs. 29.5%; RR 1.89, 95% CI 1.06\n \u2013<\/jats:bold>\n 3.37;\n P<\/jats:italic>\n = 0.032). Higher-risk groups exhibited earlier and progressively worsening renal dysfunction, with eGFR decline evident as early as week 24 and UACR elevation becoming significant by week 76, both persisting through week 108. During the 224-week cardiovascular follow-up, the combined high\/very high-risk group had significantly greater risks of both MACEs (15.2% vs. 6.8%; hazard ratio [HR] 1.86, 95% CI 1.26\n \u2013<\/jats:bold>\n 2.74,\n P<\/jats:italic>\n = 0.001) and HF (2.8% vs. 0.5%; HR 4.58, 95% CI 1.41\n \u2013<\/jats:bold>\n 14.9,\n P<\/jats:italic>\n = 0.011) compared to the low-risk group.\n <\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n This practical risk score identifies high-risk T2D patients with cardiorenal risk, including early renal function decline, to guide targeted intervention.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1768816","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:20Z","timestamp":1773812120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenhui","family":"Jiang","sequence":"first","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]},{"name":"Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province","place":["Cangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghang","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongai","family":"Gao","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingli","family":"Cheng","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhong","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang, Institute of Nephrology, Endocrinology Department of Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baocheng","family":"Chang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1513008","article-title":"Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to 2050","volume":"16","author":"Ma","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01917-8","article-title":"Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Naghavi","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/cir.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the american heart association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the american heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14060701","article-title":"Antioxidant effects of SGLT2 inhibitors on cardiovascular-kidney-metabolic (CKM) syndrome","volume":"14","author":"Guerrero-Mauvecin","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf295","article-title":"Novel cardiometabolic medications in the cardiovascular-kidney-metabolic syndrome era","volume":"110","author":"Pohlman","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.05.002","article-title":"Mineralocorticoid receptor antagonists and aldosterone synthase inhibitors: agent comparison with implications for clinical practice and trial design","volume":"32","author":"Ferreira","year":"2026","journal-title":"J Card Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2025.05.095","article-title":"Implementation barriers to evidence-based cardiovascular-kidney-metabolic syndrome management","volume":"34","author":"Davis","year":"2025","journal-title":"Heart Lung Circ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1897","article-title":"Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 cohorts","volume":"43","author":"Jiang","year":"2020","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14925","article-title":"Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German\/Austrian Diabetes Prospective Follow-up registry","volume":"25","author":"Kress","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15860","article-title":"Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial","volume":"26","author":"Wang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: A special report from the american heart association and american college of cardiology","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.033","article-title":"Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations","volume":"9","author":"Massy","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ahj.2015.02.002","article-title":"Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo","volume":"169","author":"Bentley-Lewis","year":"2015","journal-title":"Am Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and european medicines agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Diseases"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0985","article-title":"Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria","volume":"37","author":"Krolewski","year":"2014","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0041","article-title":"Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity","volume":"47","author":"Sattar","year":"2024","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the american heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11892-021-01446-9","article-title":"Adipose tissue inflammation and cardiovascular disease: an update","volume":"22","author":"Rana","year":"2022","journal-title":"Curr Diabetes Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.05.035","article-title":"Management of obesity in cardiovascular practice: JACC focus seminar","volume":"78","author":"Despr\u00e9s","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000535772","article-title":"Mechanistic links between central obesity and cardiorenal metabolic diseases","volume":"14","author":"Al-Chalabi","year":"2024","journal-title":"Cardiorenal Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/cir.0000000000000973","article-title":"Obesity and cardiovascular disease: A scientific statement from the american heart association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.03740907","article-title":"Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence","volume":"3","author":"Orth","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac683","article-title":"Prevention of cardiorenal damage: importance of albuminuria","volume":"44","author":"Ruilope","year":"2023","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3922398","article-title":"Diabetic retinopathy is a predictor of progression of diabetic kidney disease: A systematic review and meta-analysis","volume":"2022","author":"Gupta","year":"2022","journal-title":"Int J Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12872-024-04374-0","article-title":"Early Prediction of Cardio Vascular Disease (CVD) from Diabetic Retinopathy using improvised deep Belief Network (I-DBN) with Optimum feature selection technique","volume":"25","author":"Revathi","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"Jama"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.05.004","article-title":"Development and external validation of a machine learning model for progression of CKD","volume":"7","author":"Ferguson","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.ajkd.2021.05.018","article-title":"A predictive model for progression of CKD to kidney failure based on routine laboratory tests","volume":"79","author":"Zacharias","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.01.009","article-title":"Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate","volume":"93","author":"Grams","year":"2018","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1768816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:21Z","timestamp":1773812121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1768816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":39,"alternative-id":["10.3389\/fendo.2026.1768816"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1768816","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1768816"}}